Bayer: strong operational start to the year

Group sales increase 4.1 percent (Fx& portfolio adj.) to 13.015 billion euros / EBITDA before special items advances by 44.6 percent to 4.188 billion euros / Crop Science posts substantial sales and earnings gains following the acquisition / Pharmaceuticals shows encouraging sales and earnings growth / Consumer Health below the prior-year quarter, full-year outlook confirmed / Net income declines as expected by 36.5 percent to 1.241 billion euros, held back by special items related to the acquisition and restructuring / Core earnings per share increase 13.8 percent to 2.55 euros / Business outlook for 2019 confirmed
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news